218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值

doi:10.6040/j.issn.1671-7554.0.2021.1020

摘要/Abstract

摘要： 目的探讨乳腺癌新辅助化疗(NAC)的临床价值及可能适用人群,以及NAC对雌激素受体(ER)、孕激素受体(PR)、表皮生长因子受体2(Her-2)及增殖细胞核抗原Ki-67分子标志物表达状态的影响及表达变化的预后价值。方法选取2009年1月至2017年12月就诊于山东大学齐鲁医院的女性乳腺癌患者2 928例,经纳入标准与排除标准筛选,最终纳入患者1 817例,使用COX回归分析NAC组与辅助化疗组年龄、初诊时肿瘤大小、初诊时淋巴结状态、是否绝经、淋巴结转移个数、分子分型的临床病理学指标对患者预后的影响;根据NAC对ER、PR、Her-2、Ki-67表达的影响,分析分子标志物改变的预后价值。结果与行辅助化疗相比,肿瘤≤5 cm、转移淋巴结个数≥4个及三阴性乳腺癌的患者行NAC生存获益最高;50~80岁、初诊时淋巴结为阴性、已绝经者及Her-2阳性型乳腺癌患者行NAC生存获益最低;20~49岁、肿瘤>5 cm、初诊时淋巴结为阳性、未绝经者、淋巴结转移个数<4个及Luminal型患者行NAC有高复发风险;NAC前后ER、PR、Ki-67的改变差异有统计学意义(P<0.05),Her-2的变化无统计学意义的关联(P=0.754)。NAC前后ER、PR、Her-2的改变与乳腺癌患者的OS及DFS无统计学意义的关联(P>0.05),Ki-67由低表达变为高表达患者与Ki-67表达稳定及降低患者相比,OS与DFS较差,差异有统计学意义(P<0.05)。结论可手术的乳腺癌患者并不一定均适合行NAC治疗,需根据患者年龄、肿瘤大小、淋巴结转移状态、分子分型等临床病理指标及保乳意愿综合判断生存获益。NAC可改变乳腺癌ER、PR及Ki-67的表达状态,Ki-67的表达变化可作为NAC疗效的有效预测因子。

关键词: 乳腺癌, 新辅助化疗, 分子分型, 雌激素受体, 孕激素受体, Ki-67抗原

Abstract: Objective To explore the significance of neoadjuvant chemotherapy(NAC)in the treatment of breast cancer and to identify the possible applicable population, to investigate the effects of NAC on the expressions of estrogen receptor(ER), progesterone receptor(PR), human epidermal growth factor receptor 2(Her-2)and Ki-67, and to evaluate the prognostic value of such expression changes. Methods Clinical data of 2,928 female breast cancer patients treated in our hospital during Jan. 2009 and Dec. 2017 were retrospectively analyzed. After screening with inclusion and exclusion criteria, 1,817 cases were included. COX regression was used to analyze the effects of clinicopathological indicators on the prognosis of patients in NAC group and adjuvant chemotherapy group, including age, tumor size and lymph node status at initial diagnosis, menopause, number of lymph node metastasis, and molecular classification. According to the effects of NAC on the expressions of ER, PR, Her-2 and Ki-67, the prognostic value of the changes in these molecular markers was explored. Results In the NAC group, patients with tumor size ≤5 cm, metastatic lymph nodes ≥4 and triple negative breast cancer had the highest survival benefits, while patients aged 50-80 years, with negative lymph node at initial diagnosis, menopausal and Her-2 positive had the lowest survival benefits. Patients aged 20-49 years, with tumor size >5cm, lymph node positive at initial diagnosis, premenopausal, metastatic lymph nodes <4, and Luminal type breast cancer were associated with high recurrence risk. There were significant differences in ER, PR and Ki-67 expressions before and after NAC(P<0.05), while there was no significant difference in Her-2(P=0.754). There was no significant correlation between the changes of ER, PR and Her-2 before and after NAC with overall survival(OS)and disease-free survival(DFS)(P>0.05). Compared with patients with stable and decreased expression of Ki-67, patients with low to high expression of Ki-67 had poorer survival benefits(P<0.05). Conclusion NAC is not suitable for all patients with operable breast cancer. Survival benefits should be evaluated comprehensively based on patients age, tumor size, lymph node metastasis status, molecular typing and other pathological indicators as well as breast preservation willingness. NAC can change the expressions of ER, PR and Ki-67 in breast cancer, and the expression of Ki-67 can be considered as a predictive marker of the effects of NAC.

Key words: Breast cancer, Neoadjuvant chemotherapy, Molecular subtyping, Estrogen receptor, Progesterone receptor, Ki-67 antigen

中图分类号:

R574

初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.

CHU Zhuxiu, ZHAO Wenjing, LI Xiaoyan, KONG Xiaoli, MA Tingting, JIANG Liyu, YANG Qifeng. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer[J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.

参考文献

[1] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8): 609-680.
[2] Grider JR, Piland BE, Gulick MA, et al. Brain-derived neurotrophic factor augments peristalsis by augmenting 5-HT and calcitonin gene-related peptide release [J]. Gastroenterology, 2006, 130(3): 771-780.
[3] Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States [J]. Cancer, 2015, 121(15): 2544-2552.
[4] Clough KB, Acosta-Marín V, Nos C, et al. Rates of neoadjuvant chemotherapy and oncoplastic surgery for breast cancer surgery: a French national survey [J]. Ann Surg Oncol, 2015, 22(11): 3504-3511.
[5] Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis [J]. J Natl Cancer Inst, 2005, 97(3): 188-194.
[6] Popat S, Smith IE. Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis [J]. J Natl Cancer Inst, 2005, 97(11): 858.
[7] Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
[8] Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 [J]. J Clin Oncol, 2008, 26(5): 778-785.
[9] Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 [J]. Eur J Cancer, 1994, 30A(5): 645-652.
[10] van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 [J]. J Clin Oncol, 2001, 19(22): 4224-4237.
[11] Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr, 2001(30): 96-102. doi:10.1093/oxfordjournals.jncimonographs.a003469.
[12] Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer [J]. Oncologist, 2004, 9(6): 606-616.
[13] Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study [J]. Breast Cancer Res Treat, 2011, 126(1): 185-192.
[14] Hayes DF. Prognostic and predictive factors revisited [J]. Breast, 2005, 14(6): 493-499.
[15] Payne SJ, Bowen RL, Jones JL, et al. Predictive markers in breast cancer: the present [J]. Histopathology, 2008, 52(1): 82-90.
[16] Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer [J]. Virchows Arch, 2005, 446(5): 489-496.
[17] Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer [J]. Br J Cancer, 2005, 92(1): 147-155.
[18] Taucher S, Rudas M, Mader RM, et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer [J]. Breast Cancer Res Treat, 2003, 82(3): 207-213.
[19] Wu YT, Li X, Lu LJ, et al. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: a retrospective study of 525 patients [J]. J Biomed Res, 2017,32(3):191-197.
[20] Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J]. J Clin Oncol, 1999, 17(5): 1474-1481.
[21] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. Arch Pathol Lab Med, 2007, 131(1): 18-43.
[22] Vaidya JS, Massarut S, Vaidya HJ, et al. Rethinking neoadjuvant chemotherapy for breast cancer [J]. BMJ Clin Res Ed, 2018, 360: j5913. doi:10.1136/bmj.j5913.
[23] Rouzier R, Extra JM, Klijanienko J, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes [J]. J Clin Oncol, 2002, 20(5): 1304-1310.
[24] Carey LA, Metzger R, Dees EC, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome [J]. J Natl Cancer Inst, 2005, 97(15): 1137-1142.
[25] Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27 [J]. J Clin Oncol, 2006, 24(13): 2019-2027.
[26] von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes [J]. J Clin Oncol, 2012, 30(15): 1796-1804.
[27] Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma[J]. Am Surg, 1996, 62(2): 162-165.
[28] Tacca O, Penault-Llorca F, Abrial C, et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy [J]. Oncologist, 2007, 12(6): 636-643.
[29] Hirata T, Shimizu C, Yonemori K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer [J]. Br J Cancer, 2009, 101(9): 1529-1536.
[30] Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy [J]. Breast, 2008, 17(5): 523-527.
[31] Ding YQ, Ding KJ, Qian HD, et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer [J]. PLoS One, 2020, 15(4): e0231895.
[32] Matsubara N, Mukai H, Fujii S, et al. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer [J]. Breast Cancer Res Treat, 2013, 137(1): 203-212.
[33] von Minckwitz G, Schmitt WD, Loibl S, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer [J]. Clin Cancer Res, 2013, 19(16): 4521-4531.
[34] Yamazaki N, Wada N, Yamauchi C, et al. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy [J]. Eur J Surg Oncol, 2015, 41(5): 617-624.
[35] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast cancer 2013 [J]. Ann Oncol, 2013, 24(9): 2206-2223.
[36] 姬瑶, 刘君, 杨艳芳. 158例乳腺癌新辅助化疗疗效与Ki-67截断值的相关分析[J]. 中国肿瘤临床, 2017, 44(11): 547-551. JI Yao, LIU Jun, YANG Yanfang, et al. Outcome and prognostic markers of neoadjuvant chemotherapy and cut-off value of Ki-67 in 158 breast cancer patients [J]. Chinese Journal of Clinical Oncology, 2017, 44(11): 547-551.
[37] 黄湘秦. 新辅助化疗乳腺癌对ER、PR、HER-2、Ki-67表达的影响及意义[J]. 中外医学研究, 2020, 18(26): 52-54. HUANG Xiangqin. Effects and significance of neoadjuvant chemotherapy for breast cancer on ER, PR, HER-2, Ki-67 expression [J]. Chinese and Foreign Medical Research, 2020, 18(26): 52-54
[38] 蔡耿喜, 蔡子杰, 陈前军, 等. 乳腺癌新辅助化疗的现状与进展——南方乳腺癌论坛主要议题与共识[J]. 中国普通外科杂志, 2019, 28(11): 1309-1321. CAI Gengxi, CAI Zijie, CHEN Qianjun, et al. Current status and development of chemotherapy of breast cancer: the main topics and agreements of China South Breast Cancer Symposium [J]. Chinese Journal of General Surgery, 2019, 28(11): 1309-1321.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed